e-learning
resources
Copenhagen 2005
Monday 19.09.2005
COPD - treatment III
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Using cardioselective beta-blockers in patients with cardiovascular diseases and COPD
I. V. Litvinova, J. V. Gavrilov, S. I. Ovcharenko, V. A. Sulimov, V. I. Makolkin (Moscow, Russian Federation)
Source:
Annual Congress 2005 - COPD - treatment III
Session:
COPD - treatment III
Session type:
Thematic Poster Session
Number:
1960
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. V. Litvinova, J. V. Gavrilov, S. I. Ovcharenko, V. A. Sulimov, V. I. Makolkin (Moscow, Russian Federation). Using cardioselective beta-blockers in patients with cardiovascular diseases and COPD. Eur Respir J 2005; 26: Suppl. 49, 1960
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Using cardioselective beta-blockers in patients with cardiovascular diseases and asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 69s
Year: 2007
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF?
Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD
Year: 2009
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016
Year: 2017
Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function
Source: International Congress 2018 – Cardiovascular morbidities in COPD
Year: 2018
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016
Year: 2017
The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD
Source: Eur Respir J 2010; 35: 1003-1021
Year: 2010
Use of metoprolol succinate in patients with cardiovascular diseases associated with asthma or chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 502s
Year: 2006
Coexistence of cardiovascular diseases in patients with COPD
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD
Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity
Year: 2011
Do cardiovascular drugs reduce mortality in patients with COPD in daily practice? A study in primary care
Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care
Year: 2007
Exacerbations and mortality of COPD patients with cardiovascular disease in the UK
Source: Annual Congress 2010 - Comorbidity in obstructive airway disease
Year: 2010
Effects of cardiovascular agents on respiratory function in COPD patients with concomitant coronary heart disease
Source: Eur Respir J 2002; 20: Suppl. 38, 247s
Year: 2002
The risk of hyperkalemia in COPD and asthma patients
Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases
Year: 2019
Beta blocker prescription in patients with coexisting cardiac and obstructive airways disease
Source: Eur Respir J 2004; 24: Suppl. 48, 278s
Year: 2004
Use of beta-blockers in COPD patients with heart-disease. BBEPOC study
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
The impact of cardiovascular drugs in COPD
Source: Annual Congress 2011 - Knowing COPD by heart: a relationship beyond comorbidity
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept